Recent news on

Ariad and Amgen in battle over biotech patent  -  Apr 18, 2007
BiopharmaReporter.com,In the Lilly case last May, Ariad alleged that Lilly's septic shock drug Xigris (drotrecogin alfa) and Evista (raloxifene), a treatment for osteoporosis,

Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales ...  -  Apr 16, 2007
Earthtimes.org...or OFC, Lilly) Xigris(R) (drotrecogin alfa (activated), Lilly) Yentreve(R) (duloxetine hydrochloride, Lilly) Zyprexa(R) (olanzapine, Lilly) Eli Lilly

Lilly Plans New Clinical Trial of Xigris(R)  -  Feb 26, 2007
PR Newswire Brasil (liberação de imprensa),In patients with multiple organ dysfunction, mortality rates were 26.5 percent among drotrecogin alfa (activated)-treated patients vs.

Lilly Plans New Clinical Trial of Xigris(R)  -  Feb 26, 2007
Earthtimes.org26 -- Eli Lilly and Company today announced plans for a new clinical study of Xigris(R) (drotrecogin alfa [activated]). The trial is designed to help

Management of Sepsis  -  Mar 16, 2007
New England Journal of Medicine (subscription),In the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) trial, 2 post hoc analysis of the subgroup of patients who had

Lilly Announces 2006 Adjusted EPS of $3.18 Excluding Charges and ...  -  Jan 31, 2007
Earthtimes.org...or OFC, Lilly) Xigris(R) (drotrecogin alfa (activated), Lilly) Yentreve(R) (duloxetine hydrochloride, Lilly) Zyprexa(R) (olanzapine, Lilly) Eli Lilly

Lilly Announces 2006 Adjusted EPS of $3.18 Excluding Charges and ...  -  Jan 31, 2007
Yahoo! News (press release)Lilly) Strattera® (atomoxetine hydrochloride, Lilly) Symbyax® (olanzapine fluoxetine combination, or OFC, Lilly) Xigris® (drotrecogin alfa (activated),

Health Canada Endorsed Important Safety Information on Xigris ...  -  Jan 3, 2007
DG News...prophylactic low-dose heparin is abruptly discontinued in patients to be started on Xigris® [drotrecogin alfa (activated)] therapy for severe sepsis.

Eli Lilly Responds To shaping drug guidelines allegations  Oct 19, 2006
Xigris(R) (drotrecogin alfa [activated]) from Eli Lilly and Company (NYSE: LLY) is a recombinant form of human Activated Protein C. It is administered by ... -E Canada Now, New Developments in Sepsis  Jul 21, 2006
Abstract. Goldstein B, Nadel S, Peters M, et al. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. ... -Medscape (subscription)



Jail death stirs questions of care  May 6, 2006
Now doctors give a sepsis patient the drug drotrecogin alfa (sold under the brand name Xigris) and use other treatments such as blood pressure controls and ... - Charlotte Observer

Jury Issues Verdict in Ariad v. Lilly Patent Infringement Suit  May 4, 2006
Evista(R) (raloxifene hydrochloride, Lilly) Xigris(R) (drotrecogin alfa (activated), Lilly) (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ). - PR Newswire

Lilly Vows To Appeal $65.2M Win By Ariad In Patent Fight  May 4, 2006
Indianapolis-based Lilly. Xigris (drotrecogin alfa), the only approved therapy for septic shock, sold $215 million. Further damages ... - BioWorld Online (subscription)

Lilly loses Evista, Xigris patent case; will appeal  May 5, 2006
...the case decided that a US patent held by Ariad (No 6,410,516) is valid and infringed by Evista (raloxifene) and Xigris (drotrecogin alfa), which contributed ... - Pharma Times (subscription)

Lilly Reports Q1 EPS of $.77, or 13% Growth  Apr 20, 2006
Strattera(R) (atomoxetine hydrochloride, Lilly) Symbyax(R) (olanzapine fluoxetine combination, or OFC, Lilly) Xigris(R) (drotrecogin alfa (activated), Lilly ... - MSN Money

Biosite(R) Incorporated Announces Results for the First Quarter of ...  Apr 24, 2006
...will be used in connection with a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris(R) (drotrecogin alfa [activated ... - MSN Money





COMUNICADO: Lilly and Biosite to Collaborate on Clinical Trial ...  Mar 20, 2006
...to collaborate in connection with a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris(R) (drotrecogin alfa [activated ... - Europa Press

Eli Lilly, Biosite Sign Deal To Collaborate For Clinical Trial Of ...  Mar 20, 2006
The trial, called RESPOND (Research Evaluating Serial Protein C levels in severe sepsis patients ON Drotrecogin alfa), would investigate the use of a ... - Trading Markets

Eli Lilly and Biosite team up for sepsis trial  Mar 21, 2006
...will investigate the use of a multipurpose biomarker, Protein C, to be used in connection with the administration of Xigris (drotrecogin alfa [activated]). ... - Pharmaceutical Business Review

Eli Lilly, Biosite ink collaboration agreement  Mar 20, 2006
...will collaborate in connection with a clinical trial employing a tailored therapy strategy for Lilly's severe sepsis drug, Xigris (drotrecogin alfa [activated ... - San Diego Daily Transcript (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional